尼妥珠单抗联合奈达铂同步放化疗治疗局部晚期食管癌的临床研究

摘要

Objective:To study the clinical effects of nimotuzumab combined with nadaplatin concurrent chemoradiotherapy in local advanced esophageal carcinoma. Methods:64 cases of patients with local advanced esophageal carcinoma who were admitted in our hospital were selected and randomly divided into the observation group and the control group, 32 cases in each group. The control group was treated with simple nedaplatin concurrent chemoradiotherapy while the observation group was treated with nimotuzumab combined with nadaplatin concurrent chemoradiotherapy. The treatment period of the two groups was 6wk. After treatment, the remission of pathogenetic condition, survival status and incidence of adverse reactions were compared between the two groups. Results:After treatment, RR of the observation group and the control group were 93.75% and 71.86% respectively (P<0.05); After treatment, there was no significant difference in 1~3-year local control rate between the two groups (P>0.05). The tumor-free survival rate and overall survival rate in the observation group(81.25%,93.75%) were significantly higher than those in the control group(P<0.05);The incidence rates of adverse reactions in the two groups were low and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:The curative effect of nimotuzumab combined with nadaplatin concurrent chemoradiotherapy in local advanced esophageal carcinoma is significant. It can significantly improve the tumor free and overall survival rate and adverse reactions are few. It has great significance in the clinical treatment of patients with local advanced esophageal carcinoma.%目的：探讨尼妥珠单抗联合奈达铂同步放化疗治疗局部晚期食管癌的临床效果。方法：选取局部晚期食管癌患者64例，随机分为观察组和对照组，每组32例，给予对照组单纯奈达铂同步放化疗治疗，给予观察组尼妥珠单抗联合奈达铂同步放化疗治疗，两组治疗周期为6wk。治疗后比较两组病情缓解情况、生存情况及不良反应发生情况。结果：治疗后观察组和对照组RR分别为93.75%、71.86%，有显著差异（P＜0.05）；治疗后两组1～3年局控率比较无明显差异（P＞0.05），但观察组无瘤生存率和总体生存率分别为81.25%、93.75%均显著高于对照组（P＜0.05）；两组不良反应发生率较低，不良反应发生情况比较无显著差异（P＞0.05）。结论：尼妥珠单抗联合奈达铂同步放化疗对局部晚期食管癌疗效显著，可明显提高患者无瘤生存率和总体生存率，不良反应较少，对局部晚期食管癌患者的临床治疗意义重大。